KeyBank National Association’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.82M | Buy |
8,003
+1,869
| +30% | +$333K | 0.01% | 502 |
|
|
2026
Q1 | $1.06M | Buy |
6,134
+1,171
| +24% | +$217K | ﹤0.01% | 588 |
|
|
2025
Q4 | $990K | Buy |
+4,963
| New | +$900K | ﹤0.01% | 589 |
|
|
2025
Q1 | – | Sell |
-2,102
| Closed | -$388K | – | 1156 |
|
|
2024
Q4 | $388K | Sell |
2,102
-2,226
| -51% | -$429K | ﹤0.01% | 901 |
|
|
2024
Q3 | $852K | Sell |
4,328
-618
| -12% | -$128K | ﹤0.01% | 602 |
|
|
2024
Q2 | $1.02M | Buy |
4,946
+174
| +4% | +$39.4K | ﹤0.01% | 533 |
|
|
2024
Q1 | $1.29M | Sell |
4,772
-102
| -2% | -$24.4K | 0.01% | 470 |
|
|
2023
Q4 | $1.15M | Buy |
4,874
+460
| +10% | +$90.5K | 0.01% | 484 |
|
|
2023
Q3 | $865K | Sell |
4,414
-12
| -0.3% | -$2.46K | ﹤0.01% | 513 |
|
|
2023
Q2 | $931K | Buy |
4,426
+13
| +0.3% | +$2.59K | ﹤0.01% | 507 |
|
|
2023
Q1 | $891K | Buy |
4,413
+195
| +5% | +$44.2K | ﹤0.01% | 507 |
|
|
2022
Q4 | $919K | Buy |
4,218
+443
| +12% | +$96.7K | ﹤0.01% | 489 |
|
|
2022
Q3 | $743K | Buy |
3,775
+387
| +11% | +$83.5K | ﹤0.01% | 528 |
|
|
2022
Q2 | $725K | Sell |
3,388
-257
| -7% | -$62.8K | ﹤0.01% | 538 |
|
|
2022
Q1 | $1.03M | Sell |
3,645
-59
| -2% | -$18.2K | ﹤0.01% | 498 |
|
|
2021
Q4 | $1.4M | Buy |
3,704
+55
| +2% | +$21.4K | 0.01% | 472 |
|
|
2021
Q3 | $1.51M | Buy |
3,649
+10
| +0.3% | +$4.15K | 0.01% | 443 |
|
|
2021
Q2 | $1.35M | Buy |
3,639
+116
| +3% | +$38.7K | 0.01% | 463 |
|
|
2021
Q1 | $1.02M | Buy |
3,523
+5
| +0.1% | +$1.39K | ﹤0.01% | 562 |
|
|
2020
Q4 | $879K | Buy |
3,518
+281
| +9% | +$66.9K | ﹤0.01% | 570 |
|
|
2020
Q3 | $733K | Buy |
3,237
+533
| +20% | +$111K | ﹤0.01% | 580 |
|
|
2020
Q2 | $471K | Sell |
2,704
-109
| -4% | -$17.4K | ﹤0.01% | 693 |
|
|
2020
Q1 | $355K | Sell |
2,813
-85
| -3% | -$12.7K | ﹤0.01% | 724 |
|
|
2019
Q4 | $443K | Buy |
2,898
+50
| +2% | +$6.92K | ﹤0.01% | 755 |
|
|
2019
Q3 | $377K | Sell |
2,848
-159
| -5% | -$21.3K | ﹤0.01% | 782 |
|
|
2019
Q2 | $427K | Sell |
3,007
-4
| -0.1% | -$543 | ﹤0.01% | 780 |
|
|
2019
Q1 | $437K | Buy |
3,011
+2
| +0.1% | +$263 | ﹤0.01% | 737 |
|
|
2018
Q4 | $341K | Sell |
3,009
-64
| -2% | -$8.01K | ﹤0.01% | 755 |
|
|
2018
Q3 | $413K | Buy |
3,073
+174
| +6% | +$21.5K | ﹤0.01% | 817 |
|
|
2018
Q2 | $325K | Sell |
2,899
-85
| -3% | -$9.19K | ﹤0.01% | 856 |
|
|
2018
Q1 | $319K | Buy |
2,984
+64
| +2% | +$6.9K | ﹤0.01% | 869 |
|
|
2017
Q4 | $320K | Sell |
2,920
-4
| -0.1% | -$435 | ﹤0.01% | 872 |
|
|
2017
Q3 | $316K | Buy |
+2,924
| New | +$300K | ﹤0.01% | 907 |
|
|
2014
Q4 | – | Sell |
-17,119
| Closed | -$1.02M | – | 1228 |
|
|
2014
Q3 | $1.02M | Sell |
17,119
-4,934
| -22% | -$282K | 0.01% | 611 |
|
|
2014
Q2 | $1.18M | Sell |
22,053
-4,255
| -16% | -$233K | 0.01% | 600 |
|
|
2014
Q1 | $1.59M | Sell |
26,308
-10,488
| -29% | -$611K | 0.01% | 485 |
|
|
2013
Q4 | $1.95M | Buy |
36,796
+650
| +2% | +$32.6K | 0.01% | 418 |
|
|
2013
Q3 | $1.67M | Sell |
36,146
-509,944
| -93% | -$23.4M | 0.01% | 446 |
|
|
2013
Q2 | $22.4M | Buy |
+546,090
| New | +$23.4M | 0.08% | 288 |
|
Other funds holding CRL
AI
KeyBank National Association's CRL Position: Q2 2026 in Review
KeyBank National Association increased its Charles River Laboratories (CRL) stake by 30% in Q2 2026, buying an estimated $333K and bringing the position to 8,003 shares worth $1.82M. The position accounts for 0.01% of the portfolio, ranked #502.
KeyBank National Association first reported a position in CRL in Q2 2013 and has held it in 39 quarters since. The position peaked at $22.4M in Q2 2013. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- KeyBank National Association held 8,003 shares of Charles River Laboratories worth $1.82M as of Q2 2026.
- KeyBank National Association bought 1,869 Charles River Laboratories shares in Q2 2026, an estimated $333K.
- Charles River Laboratories made up 0.01% of KeyBank National Association's portfolio in Q2 2026, its #502 holding.
- KeyBank National Association first reported a position in Charles River Laboratories in Q2 2013 and has held it in 39 quarters since.
- KeyBank National Association's Charles River Laboratories position peaked at $22.4M in Q2 2013.
- 563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.